{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:44:59Z","timestamp":1794048299496,"version":"4.8.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Istanbul University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Amyloid A (AA) amyloidosis is an organ- or life-threatening complication of chronic inflammatory disorders. Here, we review the epidemiology, causes, pathogenesis, clinical features, and diagnostic and therapeutic strategies of AA amyloidosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>The incidence of AA amyloidosis has declined due to better treatment of the underlying diseases. Histopathological examination is the gold standard of diagnosis, but magnetic resonance imaging can be used to detect cardiac involvement. There is yet no treatment option for the clearance of amyloid fibril deposits; therefore, the management strategy primarily aims to reduce serum amyloid A protein. Anti-inflammatory biologic agents have drastically expanded our therapeutic armamentarium. Kidney transplantation is preferred in patients with kidney failure, and the recurrence of amyloidosis in the allograft has become rare as transplant recipients have started to benefit from the new agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The management of AA amyloidosis has been considerably changed over the recent years due to the novel therapeutic options aiming to control inflammatory activity. New agents capable of clearing amyloid deposits from the tissues are still needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-024-01147-8","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T04:02:26Z","timestamp":1712116946000},"page":"248-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["AA Amyloidosis: A Contemporary View"],"prefix":"10.1007","volume":"26","author":[{"given":"Safak","family":"Mirioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Uludag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozge","family":"Hurdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Kumru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilay","family":"Berke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros A.","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"issue":"23","key":"1147_CR1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361\u201371. https:\/\/doi.org\/10.1056\/NEJMoa070265.","journal-title":"N Engl J Med"},{"issue":"4","key":"1147_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","volume":"44","author":"R Papa","year":"2018","unstructured":"Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin North Am. 2018;44(4):585\u2013603. https:\/\/doi.org\/10.1016\/j.rdc.2018.06.004.","journal-title":"Rheum Dis Clin North Am"},{"key":"1147_CR3","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/1471-2458-12-974","volume":"12","author":"K Hemminki","year":"2012","unstructured":"Hemminki K, Li X, F\u00f6rsti A, Sundquist J, Sundquist K. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health. 2012;12:974. https:\/\/doi.org\/10.1186\/1471-2458-12-974.","journal-title":"BMC Public Health"},{"key":"1147_CR4","doi-asserted-by":"publisher","unstructured":"Aguirre MA, Boietti BR, Nucifora E, Sorroche PB, Gonz\u00e1lez Bernaldo de Quir\u00f3s F, Giunta DH, et al. Incidence rate of amyloidosis in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort. Amyloid. 2016;23(3):184\u20137. https:\/\/doi.org\/10.1080\/13506129.2016.1207626.","DOI":"10.1080\/13506129.2016.1207626"},{"issue":"3","key":"1147_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.kint.2022.10.028","volume":"103","author":"S Karam","year":"2023","unstructured":"Karam S, Haidous M, Royal V, Leung N. Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Kidney Int. 2023;103(3):473\u201384. https:\/\/doi.org\/10.1016\/j.kint.2022.10.028.","journal-title":"Kidney Int"},{"issue":"9","key":"1147_CR6","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","volume":"95","author":"S Dasari","year":"2020","unstructured":"Dasari S, Theis JD, Vrana JA, Rech KL, Dao LN, Howard MT, et al. Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples. Mayo Clin Proc. 2020;95(9):1852\u201364. https:\/\/doi.org\/10.1016\/j.mayocp.2020.06.029.\u00a0A significant study addressing the clinical use of mass spectrometry in amyloidosis.","journal-title":"Mayo Clin Proc"},{"key":"1147_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/clep.S39981","volume":"6","author":"D Real de As\u00faa","year":"2014","unstructured":"Real de As\u00faa D, Costa R, Galv\u00e1n JM, Filigheddu MT, Trujillo D, Cadi\u00f1anos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014;6:369\u201377. https:\/\/doi.org\/10.2147\/clep.S39981.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"1147_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/rheumatology\/kead465","volume":"63","author":"M Bektas","year":"2024","unstructured":"Bektas M, Koca N, Oguz E, Sari S, Dagci G, Ince B, et al. Characteristics and course of patients with AA amyloidosis: single centre experience with 174 patients from Turkey. Rheumatology (Oxford). 2024;63(2):319\u201328. https:\/\/doi.org\/10.1093\/rheumatology\/kead465.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1147_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaip.2020.09.023","volume":"9","author":"M Delplanque","year":"2021","unstructured":"Delplanque M, Galicier L, Oziol E, Ducharme-B\u00e9nard S, Oksenhendler E, Buob D, et al. AA Amyloidosis secondary to primary immune deficiency: about 40 cases including 2 new French cases and a systematic literature review. J Allergy Clin Immunol Pract. 2021;9(2):745-52.e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.023.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"1147_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.berh.2017.12.001","volume":"31","author":"HJ Lachmann","year":"2017","unstructured":"Lachmann HJ. Periodic fever syndromes. Best Pract Res Clin Rheumatol. 2017;31(4):596\u2013609. https:\/\/doi.org\/10.1016\/j.berh.2017.12.001.\u00a0A recent review of periodic fever syndromes that are known to result in AA amyloidosis if left untreated or undertreated.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"1147_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/msj.21342","volume":"79","author":"D Bunker","year":"2012","unstructured":"Bunker D, Gorevic P. AA amyloidosis: Mount Sinai experience, 1997\u20132012. Mt Sinai J Med. 2012;79(6):749\u201356. https:\/\/doi.org\/10.1002\/msj.21342.","journal-title":"Mt Sinai J Med"},{"issue":"1","key":"1147_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13506129.2018.1429391","volume":"25","author":"N Blank","year":"2018","unstructured":"Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, R\u00f6cken C, et al. Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid. 2018;25(1):37\u201345. https:\/\/doi.org\/10.1080\/13506129.2018.1429391.","journal-title":"Amyloid"},{"key":"1147_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","volume":"10","author":"GT Westermark","year":"2015","unstructured":"Westermark GT, F\u00e4ndrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol. 2015;10:321\u201344. https:\/\/doi.org\/10.1146\/annurev-pathol-020712-163913.","journal-title":"Annu Rev Pathol"},{"issue":"6","key":"1147_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583\u201396. https:\/\/doi.org\/10.1056\/NEJMra023144.","journal-title":"N Engl J Med"},{"issue":"4","key":"1147_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","volume":"27","author":"MD Benson","year":"2020","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217\u201322. https:\/\/doi.org\/10.1080\/13506129.2020.1835263.","journal-title":"Amyloid"},{"key":"1147_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/978-3-030-41769-7_17","volume":"94","author":"GH Sack Jr","year":"2020","unstructured":"Sack GH Jr. Serum amyloid A (SAA) proteins. Subcell Biochem. 2020;94:421\u201336. https:\/\/doi.org\/10.1007\/978-3-030-41769-7_17.","journal-title":"Subcell Biochem"},{"issue":"5","key":"1147_CR17","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1182\/blood-2005-11-011932","volume":"108","author":"C Shah","year":"2006","unstructured":"Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood. 2006;108(5):1751\u20137. https:\/\/doi.org\/10.1182\/blood-2005-11-011932.","journal-title":"Blood"},{"issue":"5","key":"1147_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/mol.0000000000000331","volume":"27","author":"GS Getz","year":"2016","unstructured":"Getz GS, Krishack PA, Reardon CA. Serum amyloid A and atherosclerosis. Curr Opin Lipidol. 2016;27(5):531\u20135. https:\/\/doi.org\/10.1097\/mol.0000000000000331.","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"1147_CR19","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/art.33455","volume":"64","author":"M Connolly","year":"2012","unstructured":"Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, et al. Acute-phase serum amyloid A regulates tumor necrosis factor \u03b1 and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum. 2012;64(4):1035\u201345. https:\/\/doi.org\/10.1002\/art.33455.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1147_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00018-008-8321-x","volume":"66","author":"E Malle","year":"2009","unstructured":"Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci. 2009;66(1):9\u201326. https:\/\/doi.org\/10.1007\/s00018-008-8321-x.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"1147_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1046\/j.1432-1327.1999.00657.x","volume":"265","author":"CM Uhlar","year":"1999","unstructured":"Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265(2):501\u201323. https:\/\/doi.org\/10.1046\/j.1432-1327.1999.00657.x.","journal-title":"Eur J Biochem"},{"issue":"4","key":"1147_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3109\/13506129809007299","volume":"5","author":"DR Booth","year":"1998","unstructured":"Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid. 1998;5(4):262\u20135. https:\/\/doi.org\/10.3109\/13506129809007299.","journal-title":"Amyloid"},{"issue":"3","key":"1147_CR23","first-page":"198","volume":"45","author":"E Yilmaz","year":"2003","unstructured":"Yilmaz E, Balci B, Kutlay S, Ozen S, Ert\u00fcrk S, Oner A, et al. Analysis of the modifying effects of SAA1, SAA2 and TNF-alpha gene polymorphisms on development of amyloidosis in FMF patients. Turk J Pediatr. 2003;45(3):198\u2013202.","journal-title":"Turk J Pediatr"},{"issue":"2","key":"1147_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.kint.2021.09.007","volume":"101","author":"J Sikora","year":"2022","unstructured":"Sikora J, Kmochov\u00e1 T, Mu\u0161\u00e1lkov\u00e1 D, Pohludka M, P\u0159ikryl P, Hartmannov\u00e1 H, et al. A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney Int. 2022;101(2):349\u201359. https:\/\/doi.org\/10.1016\/j.kint.2021.09.007.","journal-title":"Kidney Int"},{"issue":"6","key":"1147_CR25","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/hmg\/4.6.1083","volume":"4","author":"S Baba","year":"1995","unstructured":"Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel allelic variant of serum amyloid A, SAA1 gamma: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995;4(6):1083\u20137. https:\/\/doi.org\/10.1093\/hmg\/4.6.1083.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"1147_CR26","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/rheumatology\/ken371","volume":"47","author":"JC van der Hilst","year":"2008","unstructured":"van der Hilst JC, Yamada T, Op den Camp HJ, van der Meer JW, Drenth JP, Simon A. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford). 2008;47(11):1651\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/ken371.","journal-title":"Rheumatology (Oxford)"},{"issue":"14","key":"1147_CR27","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1073\/pnas.1322357111","volume":"111","author":"J Lu","year":"2014","unstructured":"Lu J, Yu Y, Zhu I, Cheng Y, Sun PD. Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. Proc Natl Acad Sci U S A. 2014;111(14):5189\u201394. https:\/\/doi.org\/10.1073\/pnas.1322357111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1147_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41467-021-21129-z","volume":"12","author":"A Bansal","year":"2021","unstructured":"Bansal A, Schmidt M, Rennegarbe M, Haupt C, Liberta F, Stecher S, et al. AA amyloid fibrils from diseased tissue are structurally different from in vitro formed SAA fibrils. Nat Commun. 2021;12(1):1013. https:\/\/doi.org\/10.1038\/s41467-021-21129-z.","journal-title":"Nat Commun"},{"key":"1147_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","volume":"57","author":"MB Pepys","year":"2006","unstructured":"Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223\u201341. https:\/\/doi.org\/10.1146\/annurev.med.57.121304.131243.","journal-title":"Annu Rev Med"},{"issue":"5","key":"1147_CR30","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jmb.2006.10.101","volume":"365","author":"AL Gharibyan","year":"2007","unstructured":"Gharibyan AL, Zamotin V, Yanamandra K, Moskaleva OS, Margulis BA, Kostanyan IA, et al. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic\/necrotic pathways. J Mol Biol. 2007;365(5):1337\u201349. https:\/\/doi.org\/10.1016\/j.jmb.2006.10.101.","journal-title":"J Mol Biol"},{"issue":"2","key":"1147_CR31","doi-asserted-by":"publisher","first-page":"e55227","DOI":"10.1371\/journal.pone.0055227","volume":"8","author":"K Migita","year":"2013","unstructured":"Migita K, Agematsu K, Masumoto J, Ida H, Honda S, Jiuchi Y, et al. The contribution of SAA1 polymorphisms to Familial Mediterranean fever susceptibility in the Japanese population. PLoS ONE. 2013;8(2):e55227. https:\/\/doi.org\/10.1371\/journal.pone.0055227.","journal-title":"PLoS ONE"},{"issue":"1","key":"1147_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13023-017-0720-3","volume":"12","author":"R Papa","year":"2017","unstructured":"Papa R, Doglio M, Lachmann HJ, Ozen S, Frenkel J, Simon A, et al. A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet J Rare Dis. 2017;12(1):167. https:\/\/doi.org\/10.1186\/s13023-017-0720-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"6 Suppl 102","key":"1147_CR33","first-page":"72","volume":"34","author":"S Atoyan","year":"2016","unstructured":"Atoyan S, Hayrapetyan H, Sarkisian T, Ben-Chetrit E. MEFV and SAA1 genotype associations with clinical features of familial Mediterranean fever and amyloidosis in Armenia. Clin Exp Rheumatol. 2016;34(6 Suppl 102):72\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1147_CR34","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/art.22507","volume":"56","author":"I Touitou","year":"2007","unstructured":"Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum. 2007;56(5):1706\u201312. https:\/\/doi.org\/10.1002\/art.22507.","journal-title":"Arthritis Rheum"},{"issue":"sup1","key":"1147_CR35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/13506129.2017.1289917","volume":"24","author":"G Palladini","year":"2017","unstructured":"Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, et al. Prognostication of survival and progression to dialysis in AA amyloidosis. Amyloid. 2017;24(sup1):136\u20137. https:\/\/doi.org\/10.1080\/13506129.2017.1289917.","journal-title":"Amyloid"},{"issue":"3","key":"1147_CR36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/13506129.2017.1342235","volume":"24","author":"T Lane","year":"2017","unstructured":"Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, et al. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid. 2017;24(3):162\u20136. https:\/\/doi.org\/10.1080\/13506129.2017.1342235.","journal-title":"Amyloid"},{"issue":"8","key":"1147_CR37","first-page":"1482","volume":"33","author":"H Uda","year":"2006","unstructured":"Uda H, Yokota A, Kobayashi K, Miyake T, Fushimi H, Maeda A, et al. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol. 2006;33(8):1482\u20137.","journal-title":"J Rheumatol"},{"issue":"3","key":"1147_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1440-1827.2001.01188.x","volume":"51","author":"M Nagata","year":"2001","unstructured":"Nagata M, Shimokama T, Harada A, Koyama A, Watanabe T. Glomerular crescents in renal amyloidosis: an epiphenomenon or distinct pathology? Pathol Int. 2001;51(3):179\u201386. https:\/\/doi.org\/10.1046\/j.1440-1827.2001.01188.x.","journal-title":"Pathol Int"},{"issue":"7","key":"1147_CR39","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1093\/rheumatology\/keaa772","volume":"60","author":"OL Kukuy","year":"2021","unstructured":"Kukuy OL, Beckerman P, Dinour D, Ben-Zvi I, Livneh A. Amyloid storm: acute kidney injury and massive proteinuria, rapidly progressing to end-stage kidney disease in AA amyloidosis of familial Mediterranean fever. Rheumatology (Oxford). 2021;60(7):3235\u201342. https:\/\/doi.org\/10.1093\/rheumatology\/keaa772.\u00a0A retrospective analysis providing great insights to the very rare \u201camyloid storm.\u201d","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1147_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4253\/wjge.v13.i1.1","volume":"13","author":"DS Dahiya","year":"2021","unstructured":"Dahiya DS, Kichloo A, Singh J, Albosta M, Wani F. Gastrointestinal amyloidosis: a focused review. World J Gastrointest Endosc. 2021;13(1):1\u201312. https:\/\/doi.org\/10.4253\/wjge.v13.i1.1.","journal-title":"World J Gastrointest Endosc"},{"issue":"12","key":"1147_CR41","doi-asserted-by":"publisher","first-page":"e13469","DOI":"10.1111\/nmo.13469","volume":"30","author":"M den Braber-Ymker","year":"2018","unstructured":"den Braber-Ymker M, Heijker S, Lammens M, Croockewit S, Nagtegaal ID. Intestinal involvement in amyloidosis is a sequential process. Neurogastroenterol Motil. 2018;30(12):e13469. https:\/\/doi.org\/10.1111\/nmo.13469.","journal-title":"Neurogastroenterol Motil"},{"issue":"6","key":"1147_CR42","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00041552-200211000-00013","volume":"11","author":"PN Hawkins","year":"2002","unstructured":"Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens. 2002;11(6):649\u201355. https:\/\/doi.org\/10.1097\/00041552-200211000-00013.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"1147_CR43","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1572-0241.2007.01669.x","volume":"103","author":"EC Ebert","year":"2008","unstructured":"Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol. 2008;103(3):776\u201387. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01669.x.","journal-title":"Am J Gastroenterol"},{"issue":"17","key":"1147_CR44","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1001\/archinte.166.17.1805","volume":"166","author":"KB Shah","year":"2006","unstructured":"Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166(17):1805\u201313. https:\/\/doi.org\/10.1001\/archinte.166.17.1805.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1147_CR45","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/00005792-199107000-00002","volume":"70","author":"MA Gertz","year":"1991","unstructured":"Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991;70(4):246\u201356.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1147_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.revmed.2022.12.004","volume":"44","author":"S Georgin-Lavialle","year":"2023","unstructured":"Georgin-Lavialle S, Savey L, Buob D, Bastard JP, Fellahi S, Karras A, et al. French practical guidelines for the diagnosis and management of AA amyloidosis. Rev Med Interne. 2023;44(2):62\u201371. https:\/\/doi.org\/10.1016\/j.revmed.2022.12.004.","journal-title":"Rev Med Interne"},{"issue":"2","key":"1147_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/13506120701260224","volume":"14","author":"BP Hazenberg","year":"2007","unstructured":"Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butrimiene I, et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid. 2007;14(2):133\u201340. https:\/\/doi.org\/10.1080\/13506120701260224.","journal-title":"Amyloid"},{"issue":"4","key":"1147_CR48","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000508022","volume":"143","author":"B Wisniowski","year":"2020","unstructured":"Wisniowski B, Wechalekar A. Confirming the diagnosis of amyloidosis. Acta Haematol. 2020;143(4):312\u201321. https:\/\/doi.org\/10.1159\/000508022.","journal-title":"Acta Haematol"},{"issue":"6","key":"1147_CR49","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/art.21902","volume":"54","author":"II van Gameren","year":"2006","unstructured":"van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006;54(6):2015\u201321. https:\/\/doi.org\/10.1002\/art.21902.","journal-title":"Arthritis Rheum"},{"key":"1147_CR50","doi-asserted-by":"publisher","unstructured":"Fedotov SA, Khrabrova MS, Anpilova AO, Dobronravov VA, Rubel AA. Noninvasive diagnostics of renal amyloidosis: current state and perspectives. Int J Mol Sci. 2022;23(20). https:\/\/doi.org\/10.3390\/ijms232012662.","DOI":"10.3390\/ijms232012662"},{"issue":"9","key":"1147_CR51","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2215\/cjn.10491012","volume":"8","author":"SM Said","year":"2013","unstructured":"Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8(9):1515\u201323. https:\/\/doi.org\/10.2215\/cjn.10491012.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1147_CR52","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40620-017-0426-6","volume":"31","author":"S Sethi","year":"2018","unstructured":"Sethi S, Theis JD. Pathology and diagnosis of renal non-AL amyloidosis. J Nephrol. 2018;31(3):343\u201350. https:\/\/doi.org\/10.1007\/s40620-017-0426-6.","journal-title":"J Nephrol"},{"key":"1147_CR53","doi-asserted-by":"publisher","first-page":"e12284","DOI":"10.1590\/1414-431X2022e12284","volume":"55","author":"VA Feitosa","year":"2022","unstructured":"Feitosa VA, Neves P, Jorge LB, Noronha IL, Onuchic LF. Renal amyloidosis: a new time for a complete diagnosis. Braz J Med Biol Res. 2022;55:e12284. https:\/\/doi.org\/10.1590\/1414-431X2022e12284.","journal-title":"Braz J Med Biol Res"},{"issue":"6","key":"1147_CR54","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/PAP.0b013e3182a92dc3","volume":"20","author":"MM Picken","year":"2013","unstructured":"Picken MM. Modern approaches to the treatment of amyloidosis: the critical importance of early detection in surgical pathology. Adv Anat Pathol. 2013;20(6):424\u201339. https:\/\/doi.org\/10.1097\/PAP.0b013e3182a92dc3.","journal-title":"Adv Anat Pathol"},{"issue":"12","key":"1147_CR55","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1681\/asn.2006050460","volume":"17","author":"LM Dember","year":"2006","unstructured":"Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006;17(12):3458\u201371. https:\/\/doi.org\/10.1681\/asn.2006050460.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"1147_CR56","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1111\/imj.15974","volume":"52","author":"MS Taylor","year":"2022","unstructured":"Taylor MS, Sidiqi H, Hare J, Kwok F, Choi B, Lee D, et al. Current approaches to the diagnosis and management of amyloidosis. Intern Med J. 2022;52(12):2046\u201367. https:\/\/doi.org\/10.1111\/imj.15974.","journal-title":"Intern Med J"},{"issue":"4","key":"1147_CR57","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1136\/jclinpath-2014-202722","volume":"68","author":"JA Gilbertson","year":"2015","unstructured":"Gilbertson JA, Theis JD, Vrana JA, Lachmann H, Wechalekar A, Whelan C, et al. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. J Clin Pathol. 2015;68(4):314\u20137. https:\/\/doi.org\/10.1136\/jclinpath-2014-202722.","journal-title":"J Clin Pathol"},{"issue":"8","key":"1147_CR58","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/jclinpath-2014-202231","volume":"67","author":"MP Owen-Casey","year":"2014","unstructured":"Owen-Casey MP, Sim R, Cook HT, Roufosse CA, Gillmore JD, Gilbertson JA, et al. Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies. J Clin Pathol. 2014;67(8):661\u20136. https:\/\/doi.org\/10.1136\/jclinpath-2014-202231.","journal-title":"J Clin Pathol"},{"issue":"14","key":"1147_CR59","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1182\/blood-2014-11-609883","volume":"125","author":"C Fern\u00e1ndez de Larrea","year":"2015","unstructured":"Fern\u00e1ndez de Larrea C, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood. 2015;125(14):2239\u201344. https:\/\/doi.org\/10.1182\/blood-2014-11-609883.","journal-title":"Blood"},{"issue":"3","key":"1147_CR60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/MNH.0b013e32835fe37c","volume":"22","author":"S Sethi","year":"2013","unstructured":"Sethi S, Vrana JA, Theis JD, Dogan A. Mass spectrometry based proteomics in the diagnosis of kidney disease. Curr Opin Nephrol Hypertens. 2013;22(3):273\u201380. https:\/\/doi.org\/10.1097\/MNH.0b013e32835fe37c.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"Suppl 1","key":"1147_CR61","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.amjmed.2022.01.004","volume":"135","author":"S Law","year":"2022","unstructured":"Law S, Gillmore JD. When to suspect and how to approach a diagnosis of amyloidosis. Am J Med. 2022;135(Suppl 1):S2-s8. https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.004.","journal-title":"Am J Med"},{"issue":"8","key":"1147_CR62","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/nejm199008233230803","volume":"323","author":"PN Hawkins","year":"1990","unstructured":"Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323(8):508\u201313. https:\/\/doi.org\/10.1056\/nejm199008233230803.","journal-title":"N Engl J Med"},{"issue":"4","key":"1147_CR63","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol. 2005;79(4):319\u201328. https:\/\/doi.org\/10.1002\/ajh.20381.","journal-title":"Am J Hematol"},{"issue":"3","key":"1147_CR64","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1136\/hrt.2005.061911","volume":"92","author":"E Perugini","year":"2006","unstructured":"Perugini E, Rapezzi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart. 2006;92(3):343\u20139. https:\/\/doi.org\/10.1136\/hrt.2005.061911.","journal-title":"Heart"},{"key":"1147_CR65","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"1","key":"1147_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1148\/radiol.2020202903","volume":"298","author":"JC Weinreb","year":"2021","unstructured":"Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, et al. Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2021;298(1):28\u201335. https:\/\/doi.org\/10.1148\/radiol.2020202903.","journal-title":"Radiology"},{"issue":"2","key":"1147_CR67","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/circulationaha.109.930636","volume":"122","author":"AS Flett","year":"2010","unstructured":"Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122(2):138\u201344. https:\/\/doi.org\/10.1161\/circulationaha.109.930636.","journal-title":"Circulation"},{"issue":"3","key":"1147_CR68","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/s0049-0172(05)80042-3","volume":"23","author":"A Livneh","year":"1993","unstructured":"Livneh A, Zemer D, Langevitz P, Shemer J, Sohar E, Pras M. Colchicine in the treatment of AA and AL amyloidosis. Semin Arthritis Rheum. 1993;23(3):206\u201314. https:\/\/doi.org\/10.1016\/s0049-0172(05)80042-3.","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"1147_CR69","first-page":"2051","volume":"20","author":"K Berglund","year":"1993","unstructured":"Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10\u201321 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol. 1993;20(12):2051\u20137.","journal-title":"J Rheumatol"},{"issue":"6","key":"1147_CR70","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10067-003-0763-9","volume":"22","author":"T Nakamura","year":"2003","unstructured":"Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2003;22(6):371\u20135. https:\/\/doi.org\/10.1007\/s10067-003-0763-9.","journal-title":"Clin Rheumatol"},{"issue":"9275","key":"1147_CR71","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/s0140-6736(00)05252-1","volume":"358","author":"JD Gillmore","year":"2001","unstructured":"Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358(9275):24\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(00)05252-1.","journal-title":"Lancet"},{"key":"1147_CR72","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1-S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","DOI":"10.1016\/j.kint.2021.05.021"},{"issue":"18","key":"1147_CR73","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/nejm197410312911803","volume":"291","author":"D Zemer","year":"1974","unstructured":"Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med. 1974;291(18):932\u20134. https:\/\/doi.org\/10.1056\/nejm197410312911803.","journal-title":"N Engl J Med"},{"issue":"3","key":"1147_CR74","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","volume":"45","author":"YY Leung","year":"2015","unstructured":"Leung YY, Yao Hui LL, Kraus VB. Colchicine\u2013update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341\u201350. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.013.","journal-title":"Semin Arthritis Rheum"},{"issue":"16","key":"1147_CR75","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/nejm198604173141601","volume":"314","author":"D Zemer","year":"1986","unstructured":"Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314(16):1001\u20135. https:\/\/doi.org\/10.1056\/nejm198604173141601.","journal-title":"N Engl J Med"},{"issue":"12","key":"1147_CR76","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/art.1780371215","volume":"37","author":"A Livneh","year":"1994","unstructured":"Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum. 1994;37(12):1804\u201311. https:\/\/doi.org\/10.1002\/art.1780371215.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1147_CR77","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3109\/0886022x.2013.811345","volume":"35","author":"S Unverdi","year":"2013","unstructured":"Unverdi S, Inal S, Ceri M, Unverdi H, Batgi H, Tuna R, et al. Is colchicine therapy effective in all patients with secondary amyloidosis? Ren Fail. 2013;35(8):1071\u20134. https:\/\/doi.org\/10.3109\/0886022x.2013.811345.","journal-title":"Ren Fail"},{"issue":"7","key":"1147_CR78","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/art.11163","volume":"48","author":"JE Gottenberg","year":"2003","unstructured":"Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003;48(7):2019\u201324. https:\/\/doi.org\/10.1002\/art.11163.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1147_CR79","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.amjmed.2009.11.010","volume":"123","author":"A Fern\u00e1ndez-Nebro","year":"2010","unstructured":"Fern\u00e1ndez-Nebro A, Oliv\u00e9 A, Castro MC, Varela AH, Riera E, Irigoyen MV, et al. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med. 2010;123(5):454\u201361. https:\/\/doi.org\/10.1016\/j.amjmed.2009.11.010.","journal-title":"Am J Med"},{"issue":"34","key":"1147_CR80","doi-asserted-by":"publisher","first-page":"e7859","DOI":"10.1097\/md.0000000000007859","volume":"96","author":"SN Esatoglu","year":"2017","unstructured":"Esatoglu SN, Hatemi G, Ugurlu S, Gokturk A, Tascilar K, Ozdogan H. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: a STROBE-compliant observational study. Medicine (Baltimore). 2017;96(34):e7859. https:\/\/doi.org\/10.1097\/md.0000000000007859.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1147_CR81","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3109\/13506129.2014.1002031","volume":"22","author":"A Courties","year":"2015","unstructured":"Courties A, Grateau G, Philippe P, Flipo RM, Astudillo L, Aubry-Rozier B, et al. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid. 2015;22(2):84\u201392. https:\/\/doi.org\/10.3109\/13506129.2014.1002031.","journal-title":"Amyloid"},{"issue":"1","key":"1147_CR82","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/14397595.2013.854048","volume":"24","author":"Y Okuda","year":"2014","unstructured":"Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24(1):137\u201343. https:\/\/doi.org\/10.3109\/14397595.2013.854048.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"1147_CR83","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.crohns.2009.11.009","volume":"4","author":"I Serra","year":"2010","unstructured":"Serra I, Oller B, Ma\u00f1osa M, Naves JE, Zabana Y, Cabr\u00e9 E, et al. Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis. 2010;4(3):269\u201374. https:\/\/doi.org\/10.1016\/j.crohns.2009.11.009.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"1147_CR84","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/art.39995","volume":"69","author":"I Ben-Zvi","year":"2017","unstructured":"Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, et al. Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2017;69(4):854\u201362. https:\/\/doi.org\/10.1002\/art.39995.\u00a0Randomized controlled trial of anakinra in patients with colchicine-resistant FMF which is a known cause of AA amyloidosis, especially in the Mediterranean basin.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"1147_CR85","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1136\/ard.2011.149922","volume":"70","author":"EJ Bodar","year":"2011","unstructured":"Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis. 2011;70(12):2155\u20138. https:\/\/doi.org\/10.1136\/ard.2011.149922.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1147_CR86","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.25057","volume":"62","author":"B Neven","year":"2010","unstructured":"Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258\u201367. https:\/\/doi.org\/10.1002\/art.25057.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1147_CR87","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/art.23475","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008;58(5):1516\u201320. https:\/\/doi.org\/10.1002\/art.23475.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1147_CR88","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(9):2486\u201396. https:\/\/doi.org\/10.1002\/art.38042.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1147_CR89","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","volume":"157","author":"PJ Hashkes","year":"2012","unstructured":"Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533\u201341. https:\/\/doi.org\/10.7326\/0003-4819-157-8-201210160-00003.","journal-title":"Ann Intern Med"},{"issue":"20","key":"1147_CR90","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","volume":"378","author":"F De Benedetti","year":"2018","unstructured":"De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378(20):1908\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1706314.\u00a0Landmark study of canakinumab for the treatment of periodic fever syndromes.","journal-title":"N Engl J Med"},{"issue":"25","key":"1147_CR91","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1205099.","journal-title":"N Engl J Med"},{"issue":"8","key":"1147_CR92","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"HM Hoffman","year":"2008","unstructured":"Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58(8):2443\u201352. https:\/\/doi.org\/10.1002\/art.23687.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1147_CR93","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1002\/art.23620","volume":"58","author":"R Goldbach-Mansky","year":"2008","unstructured":"Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008;58(8):2432\u201342. https:\/\/doi.org\/10.1002\/art.23620.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1147_CR94","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10020-018-0047-0","volume":"24","author":"GH Sack Jr","year":"2018","unstructured":"Sack GH Jr. Serum amyloid A - a review. Mol Med. 2018;24(1):46. https:\/\/doi.org\/10.1186\/s10020-018-0047-0.","journal-title":"Mol Med"},{"issue":"23","key":"1147_CR95","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa065644","volume":"356","author":"LM Dember","year":"2007","unstructured":"Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356(23):2349\u201360. https:\/\/doi.org\/10.1056\/NEJMoa065644.","journal-title":"N Engl J Med"},{"key":"1147_CR96","unstructured":"(2016) Bellus Health: Phase 3 Results of Kiacta for AA Amyloidosis. https:\/\/www.drugdiscoverytrends.com\/bellus-health-phase-3-results-of-kiacta-for-aa-amyloidosis\/. Accessed February 9, 2024."},{"issue":"10","key":"1147_CR97","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1073\/pnas.92.10.4299","volume":"92","author":"GA Tennent","year":"1995","unstructured":"Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A. 1995;92(10):4299\u2013303. https:\/\/doi.org\/10.1073\/pnas.92.10.4299.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1147_CR98","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","volume":"148","author":"JD Gillmore","year":"2010","unstructured":"Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol. 2010;148(5):760\u20137. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08036.x.","journal-title":"Br J Haematol"},{"issue":"12","key":"1147_CR99","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid p component. N Engl J Med. 2015;373(12):1106\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1504942.\u00a0Phase 1 trial of anti-SAP antibodies that are aimed to clear amyloid deposits from the affected tissues.","journal-title":"N Engl J Med"},{"key":"1147_CR100","doi-asserted-by":"publisher","unstructured":"Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci Transl Med. 2018;10(422). https:\/\/doi.org\/10.1126\/scitranslmed.aan3128.","DOI":"10.1126\/scitranslmed.aan3128"},{"issue":"8","key":"1147_CR101","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/bph.14956","volume":"177","author":"D Richards","year":"2020","unstructured":"Richards D, Bamford M, Liefaard L, Haque N, Lewis G, Storey J, et al. Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap. Br J Pharmacol. 2020;177(8):1853\u201364. https:\/\/doi.org\/10.1111\/bph.14956.","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"1147_CR102","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/13506129.2011.574354075","volume":"18","author":"B Kluve-Beckerman","year":"2011","unstructured":"Kluve-Beckerman B, Du Hardwick, L, Benson MD. AA amyloidosis: potential therapy with antisense oligonucleotides. Amyloid. 2011;18(Suppl 1):200\u20132. https:\/\/doi.org\/10.3109\/13506129.2011.574354075.","journal-title":"Amyloid"},{"issue":"2","key":"1147_CR103","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2215\/cjn.02470607","volume":"3","author":"G Boll\u00e9e","year":"2008","unstructured":"Boll\u00e9e G, Guery B, Joly D, Snanoudj R, Terrier B, Allouache M, et al. Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. Clin J Am Soc Nephrol. 2008;3(2):375\u201381. https:\/\/doi.org\/10.2215\/cjn.02470607.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1147_CR104","doi-asserted-by":"publisher","first-page":"444","DOI":"10.5301\/ijao.5000091","volume":"35","author":"M Gursu","year":"2012","unstructured":"Gursu M, Yelken B, Caliskan Y, Kazancioglu R, Yazici H, Kilicaslan I, et al. Outcome of patients with amyloidosis after renal transplantation: a single-center experience. Int J Artif Organs. 2012;35(6):444\u20139. https:\/\/doi.org\/10.5301\/ijao.5000091.","journal-title":"Int J Artif Organs"},{"issue":"8","key":"1147_CR105","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1097\/tp.0000000000003043","volume":"104","author":"I Sarihan","year":"2020","unstructured":"Sarihan I, Caliskan Y, Mirioglu S, Ozluk Y, Senates B, Seyahi N, et al. Amyloid A amyloidosis after renal transplantation: an important cause of mortality. Transplantation. 2020;104(8):1703\u201311. https:\/\/doi.org\/10.1097\/tp.0000000000003043.","journal-title":"Transplantation"},{"key":"1147_CR106","doi-asserted-by":"publisher","unstructured":"Schwarz C, Georgin-Lavialle S, Lombardi Y, Marion O, Jambon F, Legendre C, et al. Kidney transplantation in patients with AA amyloidosis: outcomes in a French multicenter cohort. Am J Kidney Dis. 2023. https:\/\/doi.org\/10.1053\/j.ajkd.2023.07.020.\u00a0A very recent report showing the decline of recurrent AA amyloidosis in allografts due to better diagnosis and treatment of the underlying disorders.","DOI":"10.1053\/j.ajkd.2023.07.020"},{"issue":"1","key":"1147_CR107","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.transproceed.2006.10.021","volume":"39","author":"A Haq","year":"2007","unstructured":"Haq A, Hussain S, Meskat B, Mohan P, Conlon P, Hickey DP. Complications of renal transplantation in patients with amyloidosis. Transplant Proc. 2007;39(1):120\u20134. https:\/\/doi.org\/10.1016\/j.transproceed.2006.10.021.","journal-title":"Transplant Proc"},{"issue":"41","key":"1147_CR108","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000005108","volume":"95","author":"C Garrouste","year":"2016","unstructured":"Garrouste C, Anglicheau D, Kamar N, Bachelier C, Rivalan J, Pereira B, et al. Anti-TNF\u03b1 therapy for chronic inflammatory disease in kidney transplant recipients: clinical outcomes. Medicine (Baltimore). 2016;95(41): e5108. https:\/\/doi.org\/10.1097\/md.0000000000005108.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1147_CR109","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfac335","volume":"38","author":"S Mirioglu","year":"2023","unstructured":"Mirioglu S, Dirim AB, Bektas M, Demir E, Tor YB, Ozluk Y, et al. Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study. Nephrol Dial Transplant. 2023;38(5):1327\u201336. https:\/\/doi.org\/10.1093\/ndt\/gfac335.\u00a0The largest study on the efficacy and safety of IL-1 blockers in kidney transplant recipients suffering from FMF and AA amyloidosis.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1147_CR110","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3810\/pgm.2012.07.2579","volume":"124","author":"S Wason","year":"2012","unstructured":"Wason S, Digiacinto JL, Davis MW. Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects. Postgrad Med. 2012;124(4):189\u201396. https:\/\/doi.org\/10.3810\/pgm.2012.07.2579.","journal-title":"Postgrad Med"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-024-01147-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-024-01147-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-024-01147-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T03:27:31Z","timestamp":1719890851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-024-01147-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":110,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1147"],"URL":"https:\/\/doi.org\/10.1007\/s11926-024-01147-8","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"23 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Outside the submitted work, SM received support for attending meetings and travel from Amgen and Sanofi Genzyme. GK received honoraria from Baxter, and support for attending meetings and travel from Amgen and Abdi Ibrahim Otsuka. AG received honoraria for advisory board meetings and speaker\u2019s fees from Novartis, Sobi, and R-Pharm. Remaining authors have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}